The overall objective of this project is to identify new, more effective medical countermeasures for the acute seizures produced by organophosphate (OP) anticholinesterase inhibitor and GABAA receptor antagonist chemical threat agents. By preventing or stopping the acute seizures, these countermeasures will improve the survival and long-term outcome of individuals exposed to seizure-inducing doses of these agents. We have selected two OP agents diisopropylfluorophosphate (DFP) and soman (0-pinacolyl methylphosphonofluoridate;GD) and one GABAA receptor antagonist tetramethylenedisulfotetramine (TETS) to represent the two broad classes of chemical threat agents. Soman, a representative of the OP neurotoxin chemical warfare agents (""""""""nerve agents""""""""), is classified as a Schedule 1 substance under the Chemical Weapons Convention of 1993. DFP, while less potent than the nerve agents in the Chemical Weapons Convention toxic chemicals list, has nearly identical effects. As a volatile agent that could rapidly spread inside closed areas, it could cause many injuries and deaths and is therefore a credible threat agent. TETS, a representative of the GABAA receptor antagonist convulsants is a highly lethal toxin that has been used as a rodenticide but is now banned in most countries of the world. Nevertheless, lethal poisoning with TETS occur regularly. On a mg basis, TETS is equal in lethality to the OP chemical warfare agents. Recently, we have had the opportunity to characterize the convulsant activity of TETS in mice and rats when administered by the i.p., i.v., oral and intracerebroventricular routes. As a result of this work, we have developed the first animal model in which to evaluate potential treatments for TETS when administered before and after exposure. In this project, DFP and soman are administered to rats and TETS is administered to mice to induce seizures. The animals are treated before or at various intervals following exposure with various potential therapeutic agents (or combinations) to assess the ability of the test agent to prevent or terminate behavioral or electrographic seizure activity. Testing in the OP models occurs in a step-wise fashion, first against DFP seizures because DFP has reduced safety concerns and can be used in a regular laboratory environment, and then with soman, which requires extreme safety precautions available at the US Army Medical Research Institute of Chemical Defense. All test agents are compared with diazepam, the current standard of care for the emergency treatment of chemical exposure seizures. Diazepam may be effective if administered early in the course of seizures but seizures may recur and the drug may be inactive if administered later in the course of seizures. In addition, diazepam can depress blood pressure and respiration. A further concern is that diazepam is erratically absorbed when administered by the i.m. route (as with the injector systems stockpiled for use in mass casualty situations). We are seeking agents (or combinations) that improve upon diazepam with respect to any of these liabilities. We have identified a series of potential therapies (Tier 1) that are either currently approved for sale in the U.S. or for which human data is available and can therefore be rapidly deployed. In addition, novel potential therapies that are new molecular entities (Tier 2) will be developed in Core B and Project 3. Therapies that exhibit superior activity to diazepam will be studied in Project 2 for their ability to mitigate seizure-induced brain damage. Finally, in order to advance the most promising therapies, we will complete various additional studies, including formulation development and safety, toxicology and ADME studies in conjunction with Cores A and B, to assist in making go/no-go decisions regarding further development.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
United States
Zip Code
Tu, Ranran; Armstrong, Jillian; Lee, Kin Sing Stephen et al. (2018) Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci Rep 8:5279
Hampe, Alexander E; Li, Zidong; Sethi, Sunjay et al. (2018) A Microfluidic Platform to Study Astrocyte Adhesion on Nanoporous Gold Thin Films. Nanomaterials (Basel) 8:
Hobson, Brad A; Rowland, Douglas J; Supasai, Suangsuda et al. (2018) A magnetic resonance imaging study of early brain injury in a rat model of acute DFP intoxication. Neurotoxicology 66:170-178
Moeller, Benjamin; Espelien, Brenna; Weber, Waylon et al. (2018) The pharmacokinetics of ketamine following intramuscular injection to F344 rats. Drug Test Anal :
Pressly, Brandon; Nguyen, Hai M; Wulff, Heike (2018) GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Arch Toxicol 92:833-844
Dhir, Ashish; Rogawski, Michael A (2018) Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. Epilepsia 59:935-944
Nik, Atefeh Mousavi; Pressly, Brandon; Singh, Vikrant et al. (2017) Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye. Mol Pharmacol 92:88-99
Zhou, Yong; Liu, Tian; Duan, Jia-Xi et al. (2017) Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice. Shock 47:638-645
Barnych, Bogdan; Vasylieva, Natalia; Joseph, Tom et al. (2017) Development of Tetramethylenedisulfotetramine (TETS) Hapten Library: Synthesis, Electrophysiological Studies, and Immune Response in Rabbits. Chemistry 23:8466-8472
Chapman, Christopher A R; Wang, Ling; Chen, Hao et al. (2017) Nanoporous Gold Biointerfaces: Modifying Nanostructure to Control Neural Cell Coverage and Enhance Electrophysiological Recording Performance. Adv Funct Mater 27:

Showing the most recent 10 out of 85 publications